Please assess the completion status of the following clinical trial:

Trial Title: Treatment for Clostridium-difficile Infection With IMM529

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Unformed stools (≥3 loose stools in 24 hours at diagnosis)~3. Positive stool testing for C. difficile: PCR and Toxin B positive; or PCR and GDH positive.~4. Up to 3 weeks of diagnosis with at least 20 subjects within 72 hours of diagnosis~5. Patient or legal representative must have read, understood, and provided written informed consent after the nature of the study has been fully explained.~Exclusion Criteria:~1. History of chronic diarrheal illness such as ulcerative colitis or Crohn's disease~2. Known concurrent severe organ insufficiency:~   Liver: Decompensated cirrhosis (Any complication of cirrhosis or Child Score ≥7).~   Cardiovascular: New York Heart Association (NYHA) class IV heart failure, or Ejection fraction \<30%.~   Respiratory: Severe exercise restriction (ie, unable to climb stairs or perform household duties); chronic hypoxia, hypercapnia, severe pulmonary hypertension (\>40 mmHg); or respirator dependency Renal: Receiving chronic dialysis or GFR \< 15 mL/min/1.73m2~3. Other etiology of diarrhea.~4. Fulminant CDI, as defined by any of the following attributable to CDI:~   1. Hypotension (Mean arterial pressure \< 65mmHg)~  2. Ileus or significant abdominal distention~  3. Toxic megacolon~  4. End organ damage/failure:~   Respiratory - Need for mechanical ventilation. Cardiac - Pulmonary edema. Renal - Serum creatinine increase \>3x Baseline, GFR decrease \>50%, urinary output \<0.5mL/kg/hr \> 12hrs. Hepatic - Liver failure (INR\>1.5, Hepatic encephalopathy), decompensation of cirrhosis, bilirubin \> 2.5mg/dL.~5. Severe Clostridium difficile colitis with imminent surgery planned in less than 24 hours.~6. Immunocompromise due to: immunosuppressants, chemotherapy, radiation in the last 3 months, long-term steroids (\>10mg \>3 months) or high-dose steroids (\>40mg \> 3 weeks), leukemia or lymphoma in the last 5 years, or HIV.~7. Any active malignancy within the last 5 years apart from localized skin cancer (squamous cell carcinoma or basal cell carcinoma) that was fully excised.~8. Positive pregnancy test within 24 hours of study infusion or an unwillingness to undergo pregnancy testing in females of child-bearing potential. Females capable of child-bearing must agree not to become pregnant from the time of study enrollment until at least 28 days after completion of study treatment period. If a woman is sexually active and has no history of hysterectomy or tubal ligation, she must agree to use 2 acceptable contraceptives (see section 7.4.1.) while participating in the study and for 28 days following the last dose of study drug.~9. Breastfeeding~10. Receipt of other investigational study agent within previous 30 days.~11. Cow milk allergy, lactose intolerance or any known or suspected hypersensitivity to study products~12. Any other condition that in the opinion of the investigator would jeopardize the safety or rights of the patient participating in the study or make it unlikely the patient could complete the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Treatment arm A (Type: EXPERIMENTAL): IMM-529, 1000 mg three times daily, orally
- Treatment arm B (Type: PLACEBO_COMPARATOR): Matching Placebo, three times daily, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).